{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T20:59:55Z","timestamp":1780520395258,"version":"3.54.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,11,30]],"date-time":"2018-11-30T00:00:00Z","timestamp":1543536000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1007\/s00467-018-4116-y","type":"journal-article","created":{"date-parts":[[2018,11,30]],"date-time":"2018-11-30T05:39:01Z","timestamp":1543556341000},"page":"475-486","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet in pediatric patients with chronic kidney disease and secondary hyperparathyroidism receiving dialysis"],"prefix":"10.1007","volume":"34","author":[{"given":"Bradley A.","family":"Warady","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet N.","family":"Iles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gema","family":"Ariceta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastian","family":"Dehmel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Hidalgo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xun","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Laskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahnaz","family":"Shahinfar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Vande Walle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franz","family":"Schaefer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,30]]},"reference":[{"issue":"4","key":"4116_CR1","doi-asserted-by":"publisher","first-page":"913","DOI":"10.2215\/CJN.06040710","volume":"6","author":"J Cunningham","year":"2011","unstructured":"Cunningham J, Locatelli F, Rodriguez M (2011) Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol 6(4):913\u2013921","journal-title":"Clin J Am Soc Nephrol"},{"issue":"11","key":"4116_CR2","doi-asserted-by":"publisher","first-page":"763","DOI":"10.2165\/00148581-200305110-00005","volume":"5","author":"CP Sanchez","year":"2003","unstructured":"Sanchez CP (2003) Secondary hyperparathyroidism in children with chronic renal failure: pathogenesis and treatment. Paediatr Drugs 5(11):763\u2013776","journal-title":"Paediatr Drugs"},{"issue":"10","key":"4116_CR3","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1359\/jbmr.1999.14.10.1680","volume":"14","author":"BD Kuizon","year":"1999","unstructured":"Kuizon BD, Salusky IB (1999) Growth retardation in children with chronic renal failure. J Bone Miner Res 14(10):1680\u20131690","journal-title":"J Bone Miner Res"},{"issue":"1","key":"4116_CR4","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/ki.1987.176","volume":"32","author":"IB Salusky","year":"1987","unstructured":"Salusky IB, Fine RN, Kangarloo H, Gold R, Paunier L, Goodman WG, Brill JE, Gilli G, Slatopolsky E, Coburn JW (1987) \u201cHigh-dose\u201d calcitriol for control of renal osteodystrophy in children on CAPD. Kidney Int 32(1):89\u201395","journal-title":"Kidney Int"},{"issue":"1","key":"4116_CR5","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1161\/01.CIR.0000020222.63035.C0","volume":"106","author":"J Oh","year":"2002","unstructured":"Oh J, Wunsch R, Turzer M, Bahner M, Raggi P, Querfeld U, Mehls O, Schaefer F (2002) Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure. Circulation 106(1):100\u2013105","journal-title":"Circulation"},{"issue":"11","key":"4116_CR6","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/nrneph.2011.139","volume":"7","author":"CP Schmitt","year":"2011","unstructured":"Schmitt CP, Mehls O (2011) Mineral and bone disorders in children with chronic kidney disease. Nat Rev Nephrol 7(11):624\u2013634","journal-title":"Nat Rev Nephrol"},{"key":"4116_CR7","unstructured":"Sensipar\u00ae (cinacalcet) (2017) Full prescribing information. Amgen Inc., Thousand Oaks"},{"issue":"4","key":"4116_CR8","doi-asserted-by":"publisher","first-page":"e1001436","DOI":"10.1371\/journal.pmed.1001436","volume":"10","author":"SC Palmer","year":"2013","unstructured":"Palmer SC, Nistor I, Craig JC, Pellegrini F, Messa P, Tonelli M, Covic A, Strippoli GF (2013) Cinacalcet in patients with chronic kidney disease: a cumulative meta-analysis of randomized controlled trials. PLoS Med 10(4):e1001436","journal-title":"PLoS Med"},{"key":"4116_CR9","first-page":"CD006254","volume":"12","author":"AE Ballinger","year":"2014","unstructured":"Ballinger AE, Palmer SC, Nistor I, Craig JC, Strippoli GF (2014) Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients. Cochrane Database Syst Rev 12:CD006254","journal-title":"Cochrane Database Syst Rev"},{"key":"4116_CR10","unstructured":"KDIGO 2017 Clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease\u2013mineral and bone disorder (CKD-MBD). Kidney International Supplements. \n                    http:\/\/kdigo.org\/wp-content\/uploads\/2017\/02\/2017-KDIGO-CKD-MBD-GL-Update.pdf\n                    \n                  . Accessed 5 Oct 2017"},{"issue":"2","key":"4116_CR11","doi-asserted-by":"publisher","first-page":"e401","DOI":"10.1097\/MD.0000000000000401","volume":"94","author":"AA Alharthi","year":"2015","unstructured":"Alharthi AA, Kamal NM, Abukhatwah MW, Sherief LM (2015) Cinacalcet in pediatric and adolescent chronic kidney disease: a single-center experience. Medicine 94(2):e401","journal-title":"Medicine"},{"issue":"10","key":"4116_CR12","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1007\/s00467-007-0742-5","volume":"23","author":"DM Silverstein","year":"2008","unstructured":"Silverstein DM, Kher KK, Moudgil A, Khurana M, Wilcox J, Moylan K (2008) Cinacalcet is efficacious in pediatric dialysis patients. Pediatr Nephrol 23(10):1817\u20131822","journal-title":"Pediatr Nephrol"},{"issue":"1","key":"4116_CR13","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s00467-009-1294-7","volume":"25","author":"C Platt","year":"2010","unstructured":"Platt C, Inward C, McGraw M, Dudley J, Tizard J, Burren C, Saleem MA (2010) Middle-term use of Cinacalcet in paediatric dialysis patients. Pediatr Nephrol 25(1):143\u2013148","journal-title":"Pediatr Nephrol"},{"issue":"1\u20132","key":"4116_CR14","first-page":"39","volume":"26","author":"J Dotis","year":"2013","unstructured":"Dotis J, Printza N, Ghogha C, Papachristou F (2013) Short- and middle-term continuous use of cinacalcet in children on peritoneal dialysis. J Pediatr Endocrinol Metab 26(1\u20132):39\u201343","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"2","key":"4116_CR15","first-page":"65","volume":"6","author":"S Holm","year":"1979","unstructured":"Holm S (1979) A simple sequentially rejective multiple test procedure. Scand J Stat 6(2):65\u201370","journal-title":"Scand J Stat"},{"key":"4116_CR16","unstructured":"US Department of Health and Human Services (2010) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. \n                    https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf\n                    \n                  . Accessed 25 Sept 2017"},{"issue":"15","key":"4116_CR17","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1056\/NEJMoa031633","volume":"350","author":"GA Block","year":"2004","unstructured":"Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, Hercz G, Cunningham J, Abu-Alfa AK, Messa P, Coyne DW, Locatelli F, Cohen RM, Evenepoel P, Moe SM, Fournier A, Braun J, McCary LC, Zani VJ, Olson KA, Drueke TB, Goodman WG (2004) Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350(15):1516\u20131525","journal-title":"N Engl J Med"},{"issue":"1","key":"4116_CR18","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1046\/j.1523-1755.2003.00720.x","volume":"63","author":"JS Lindberg","year":"2003","unstructured":"Lindberg JS, Moe SM, Goodman WG, Coburn JW, Sprague SM, Liu W, Blaisdell PW, Brenner RM, Turner SA, Martin KJ (2003) The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. Kidney Int 63(1):248\u2013254","journal-title":"Kidney Int"},{"issue":"3","key":"4116_CR19","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1097\/01.ASN.0000050224.03126.AD","volume":"14","author":"LD Quarles","year":"2003","unstructured":"Quarles LD, Sherrard DJ, Adler S, Rosansky SJ, McCary LC, Liu W, Turner SA, Bushinsky DA (2003) The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol 14(3):575\u2013583","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"4116_CR20","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1007\/s00467-008-0810-5","volume":"23","author":"J Muscheites","year":"2008","unstructured":"Muscheites J, Wigger M, Drueckler E, Fischer DC, Kundt G, Haffner D (2008) Cinacalcet for secondary hyperparathyroidism in children with end-stage renal disease. Pediatr Nephrol 23(10):1823\u20131829","journal-title":"Pediatr Nephrol"},{"key":"4116_CR21","unstructured":"Mimpara\u00ae (cinacalcet) (2017) Summary of product characteristics. Amgen Inc., Thousand Oaks"},{"issue":"12","key":"4116_CR22","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1007\/s00467-017-3730-4","volume":"32","author":"A Kakajiwala","year":"2017","unstructured":"Kakajiwala A, Jemielita TO, Copelovitch L, Leonard MB, Furth SL, York A, Benton M, Hoofnagle AN, Windt K, Merrigan K, Lederman A, Denburg MR (2017) Variability in measures of mineral metabolism in children on hemodialysis: impact on clinical decision-making. Pediatr Nephrol 32(12):2311\u20132318","journal-title":"Pediatr Nephrol"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00467-018-4116-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-018-4116-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-018-4116-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,29]],"date-time":"2019-11-29T19:09:53Z","timestamp":1575054593000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00467-018-4116-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,30]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["4116"],"URL":"https:\/\/doi.org\/10.1007\/s00467-018-4116-y","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,30]]},"assertion":[{"value":"15 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"BAW and SS have served as consultants for Amgen Inc. JNI was an employee and stockholder of Amgen Inc. at the time the work was done. BD was an employee of Amgen Europe GmbH at the time the work was done. GH has received grant funding from Amgen Inc. XJ is an employee and stockholder of Amgen Inc. BL was the principal investigator for a clinical study site for the study described in this manuscript. JVW is a member of the Ferring Safety Board, Astellas Safety and Investigator Board for Solifenacin, Mitsubishi Safety Board, and Alexion Registry Review Board and receives research funding and is on the speakers bureau for Alexion Pharmaceuticals, Inc. FS has received personal fees from Amgen Inc. GA declares no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.The study protocol was approved by the institutional review board or independent ethics committee of each study center.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent or assent, when applicable, because the youngest participants cannot consent, was obtained from all individual participants included in the study and\/or their parent or legally acceptable representative.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"There is a plan to share data. This may include de-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request, also related data dictionaries, study protocol, statistical analysis plan, informed consent form, and\/or clinical study report. Data sharing requests relating to data in this manuscript will be considered after the publication date and (1) this product and indication (or other new use) have been granted marketing authorization in both the USA and Europe, or (2) clinical development discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for these data. Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study\/studies in scope, endpoints\/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labeling. A committee of internal advisors reviews requests. If not approved, requests may be further arbitrated by a Data Sharing Independent Review Panel. Requests that pose a potential conflict of interest or an actual or potential competitive risk may be declined at Amgen\u2019s sole discretion and without further arbitration. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized patient data and\/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the following: .","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data sharing"}}]}}